Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The CENTAurus trial is a prospective clinical study designed to address systematically some
of the relevant endocrine complications in an iron overloaded thalassemic population, primary
objective being the assessment of the effect of deferasirox therapy on glucose
metabolism/homeostasis. Other endocrine parameters complementary or supportive to the primary
objective will be assessed and analyzed during this study. A number of lab parameters related
to other axes of the endocrine system will be collected and analyzed.